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ABSTRACT
Objective: To assess the representativeness of the
Heart Protection Study (HPS) and the Collaborative
Atorvastatin Diabetes Study (CARDS) for incident statin
users.
Design: A population-based analysis with linked
register data.
Setting: Finland.
Population: 56 963 patients with diabetes initiating
statin use from 2005 to 2008.
Main outcome measures: We determined the
proportions of real-world patients who fulfilled the
eligibility criteria for HPS and CARDS trials and
assessed the cardiovascular disease (CVD) event
rates, assumed to reflect the background CVD risk,
for those eligible and ineligible. We used descriptive
statistics to identify the patient characteristics,
lipid-lowering interventions and adherence to statin
therapy.
Results: Of the real-world patients, 57% (N=32 582)
fulfilled the eligibility criteria for HPS (DM) and 49%
(N=20 499) of those without CVD for CARDS. The
patients ineligible for HPS (DM) had a higher cumulative
risk for CVD events than those eligible, whereas
regarding CARDS the cumulative risks were of similar
magnitude. The overall CVD event rates seemed to be
comparable to those in the reviewed trials. Both trials
were under-representative of women and users of
antihypertensive agents and metformin. 27% and 29% of
real-world patients had an initial statin dose
corresponding to <20 mg of simvastatin. The proportions
of patients who were deemed adherent were 57% in the
real world and 85% in both trials.
Conclusions: Only half of the real-world patients would
have qualified for the HPS (DM) and CARDS, limiting their
representativeness for clinical practice. Women and users
of antihypertensive agents and metformin were under-
represented in both trials. These deviations reflect the
changes in diabetes treatment over the years and are not
expected to modify the average treatment effects of statins
on CVD. Prescribing of lower statin doses in clinical
practice than used in the trials and lower adherence may,
however, attenuate the benefits in the real world.
BACKGROUND
For persons with diabetes, statins are widely
recommended to lower the risk of cardiovas-
cular disease (CVD) events.1–5 The absolute
risk of CVD events is higher among people
with diabetes than among those without dia-
betes, and the risk is further increased in the
presence of diabetes and prior CVD.6 7 The
current European guidelines for dyslipidae-
mia and CVD prevention recommend statin
therapy for nearly all patients with type 2 dia-
betes mellitus, as well as for those without
CVD.1–3 Only patients under the age of
40 years, with newly diagnosed type 2 dia-
betes, and without clinical complications or
other CVD risk factors, may be withheld
from statin therapy.1 In practice, at least 80%
of the patients with diabetes who begin
taking a statin seem to have no established
CVD.8 9
Strengths and limitations of this study
▪ This is the first study to assess the representa-
tiveness of the Heart Protection Study (HPS) and
the Collaborative Atorvastatin Diabetes Study
(CARDS) for real-world diabetes care.
▪ We assessed various aspects potentially affecting
the representativeness of the HPS and CARDS
trials: the trial eligibility criteria, the participant
characteristics, the statin interventions and
adherence to statin therapy.
▪ All trial eligibility criteria could not be assessed
by registry data and we may have slightly under-
estimated or overestimated the proportion of
those eligible for the trials.
▪ Our assessment represents a case study in
Finland; since the treatment practices vary
between countries, similar evaluations of the rep-
resentativeness of RCTs in other countries are
needed.
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A large meta-analysis of 14 randomised controlled
trials (RCTs) including only participants with diabetes
showed a relative reduction of 21% for major vascular
events (ie, coronary event, coronary revascularisation or
stroke) per every 1 mmol/L reduction in low-density
lipoprotein (LDL) cholesterol associated with statin
therapy.10 This meta-analysis conﬁrmed the beneﬁts of
statins in diabetic dyslipidaemia, as suggested by some
RCTs. The two landmark trials providing evidence on
the efﬁcacy of statins in preventing CVD events in dia-
betes are the subanalysis of the Heart Protection Study,
HPS (DM),11 and the the Collaborative Atorvastatin
Diabetes Study (CARDS).12 The HPS (DM) included
patients with diabetes, 51% of whom also had occlusive
arterial disease.11 In the HPS (DM) trial, simvastatin
(40 mg) reduced the rate of major vascular events by
22% during a mean follow-up of 4.8 years. In the
CARDS trial, only patients with type 2 diabetes but
without CVD were randomised and the trial reported a
37% relative reduction in major vascular events for ator-
vastatin (10 mg) for a median duration of 3.9 years.12
While the relative risk reductions for CVD events in dia-
betes associated with statin therapy seem to be broadly
the same across various patient subgroups,11 the abso-
lute beneﬁts increase in line with the patients’ back-
ground CVD risk.11 13 14
The HPS (DM) and CARDS trials are commonly cited
in clinical guidelines on statin use in diabetes,1 3 4 yet
no studies have assessed their representativeness regard-
ing real-world diabetes care. However, knowledge of
their representativeness is essential for understanding
the applicability of their ﬁndings.15 Previous research on
the representativeness of statin trials has typically
focused on demographic characteristics such as gender
and age.16–19 We wanted to expand the current knowl-
edge and studied various aspects possibly affecting the
representativeness of the HPS (DM) and CARDS trials:
the trial eligibility criteria, the participant characteristics,
the statin interventions and adherence to statin therapy.
We used data from a nationwide Finnish health register
to characterise real-world patients with diabetes initiat-
ing statin use between 2005 and 2008. We divided the
patients into those fulﬁlling and those not fulﬁlling the
eligibility criteria of the HPS (DM) and CARDS trials.
Second, to further evaluate the implications of the eligi-
bility criteria on representativeness, we determined the
occurrence of CVD events, which was assumed to reﬂect
the background CVD risk, for the eligible and ineligible
patients. Finally, we assessed the characteristics,
lipid-lowering interventions and adherence to statins
among the real-world patients with diabetes.
METHODS
Source of register data
We used the Diabetes in Finland (FinDM) database to
identify patients with diabetes who initiated statin use
between 2005 and 2008.20 The database was originally
constructed for the monitoring of diabetes epidemi-
ology, diabetes-related complications and diabetes care.
It combines nationwide data from administrative health
registers managed by the Finnish Social Insurance
Institution (SII), the National Institute for Health and
Welfare (THL) and Statistics Finland. The register data
were linked on an individual basis using personal identi-
ﬁcation codes. The study group received a pseudonym-
ous data set for its analyses. Persons with diabetes were
identiﬁed as having been either reimbursed for pur-
chases of drugs used in the treatment of diabetes
(Anatomical Therapeutic Chemical code A10) or eli-
gible for special reimbursement for medication costs
due to diabetes or having a primary or secondary hos-
pital discharge diagnosis for diabetes.20 The entitlement
for special reimbursement is based on predeﬁned cri-
teria, a written certiﬁcate by the patient’s treating phys-
ician and a review process conducted by the SII.
For all patients identiﬁed in the FinDM database, the
data included information on all reimbursed prescrip-
tion drug purchases in non-institutional settings
(between 1994 and 2011), entitlements for special reim-
bursements due to severe chronic conditions such as
coronary heart disease (CHD) (between 1964 and
2011), all hospitalisations (between 1969 and 2011), day
surgical procedures (between 1994 and 2011) and out-
patient hospital visits (between 1998 and 2011), with
diagnostic information (ICD-8-9-10), admission and dis-
charge dates and dates and causes of death (between
1971 and 2010).
We excluded women with gestational diabetes and
persons having a single purchase for an antidiabetic
drug or non-speciﬁc diabetes-related records only. The
onset of diabetes refers to the ﬁrst registration date of
diabetes in any of the aforementioned registers.
Accordingly, newly diagnosed diabetes was deﬁned as
diabetes registered 6 months or less before statin initi-
ation. The type of diabetes was classiﬁed according to
the type of antidiabetic medication purchased and the
age of onset—patients under 40 years of age at the onset
of diabetes with continuous prescription purchases for
insulin and without purchases for medications that
stimulate insulin secretion were deﬁned as having type 1
diabetes mellitus and those not fulﬁlling these criteria
were classiﬁed as having type 2 diabetes.
Ethical considerations
Permissions to collect data from the FinDM database
were obtained from the maintainers of the registers.20
As a part of a larger diabetes research project, our study
was approved by the ethics committee of the National
Institute for Health and Welfare, Finland.
Study cohort
We identiﬁed all statin naïve patients with diabetes who
made their ﬁrst statin purchase (Anatomic Therapeutic
Codes C10AA01-C10AA05, C10AA07, C10BA02)
between 2005 and 2008. This period was chosen to
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capture recently treated patients and to attain a
follow-up period comparable to those of the HPS and
CARDS trials. The ﬁrst statin purchase refers to no
statins dispensed during the preceding 3 years.21 We
deﬁned the date of the ﬁrst statin purchase as the
cohort entry date for all individuals. The follow-up time
was calculated from the cohort entry date until the ﬁrst
occurrence of the composite end point of a major car-
diovascular event or censoring due to non-CVD-related
death, permanent institutionalisation or 31 December
2010, whichever was ﬁrst.
Major cardiovascular events
We chose a composite end point of CVD events as the
outcome of interest, including acute myocardial infarc-
tion (as a primary or secondary discharge diagnosis of
International Classiﬁcation of Diseases (ICD)-10 I-21,
I-22) and/or a coronary revascularisation procedure
(procedure codes for coronary artery bypass grafting,
angioplasty or stenting), stroke (as a primary or second-
ary discharge diagnosis of ICD-10, I-60, I-61, I-63) or
CVD given as a primary cause of death (ICD-10 codes
I-20–I-25, I-46, R96, R98, G45 and I-60–I-69).22 The valid-
ity of the Hospital Discharge Register and the Causes of
Death Register for capturing CHD events and strokes is
good.23–25 The index date for the event was either the
hospital admission date or the date of out-of-hospital
death.
Variables
We extracted patient-level information on demographic
characteristics, complications and prescribed medica-
tions related to diabetes, and cardiovascular comorbid-
ities (table 1). Data were also extracted to cover the
inclusion and exclusion criteria of the HPS11 13 and
CARDS12 trials, as far as available in the registers (see
ﬁgure 1A, B and online supplementary appendix table).
For comorbidities, we used the corresponding ICD-10
codes captured in the Hospital Discharge Register.
When available, additional data from the SII Special
Reimbursement Register (including data on CHD, mod-
erate or severe hypertension, chronic heart failure,
chronic pulmonary diseases, malignancy, dementia and
psychotic disorders) and the Prescription Register (pur-
chases for speciﬁc medications used to treat hyperten-
sion, chronic pulmonary disorders, malignancies,
dementia and psychotic disorders) were used. We col-
lected data on comorbidities and vascular procedures
from the 9 years preceding the cohort entry date, as well
as data on prescriptions dispensed from the 4 months
preceding this date. We further categorised the cohort
members according to the presence of established CVD
at the time of statin initiation, that is, applicable ICD-10
codes for CHD (ie, myocardial infarction, angina pec-
toris or unstable angina pectoris), stroke, transient
ischaemic attack or peripheral vascular disease, surgical
procedure codes for coronary revascularisation, amputa-
tion or other peripheral vascular procedure due to
atherosclerosis or codes for special reimbursement due
to CHD.
We calculated adherence to statin therapy for the
cohort members as the truncated medication possession
ratio (MPR).26 We assumed a dosage of one statin tablet
per day and divided the total number of statin tablets
dispensed by the total number of days of follow-up
(since cohort entry to event occurrence or censoring).
We calculated the MPR for all those followed for event
occurrence, as well as separately for those surviving at
the end of each year of follow-up. In both cases, we cal-
culated the MPR for the period of interest and deﬁned
patients with good adherence to statin use as those with
an MPR of ≥80%, a conventional cut-off value.27 28
To study dose titration, we calculated the daily statin
doses as simvastatin equivalents,29 at statin initiation and
at the end of 1 year of follow-up, for patients surviving
for 365 days after the initiation and with at least one
reﬁll during the latter part of the follow-up year (ie,
between 180 and 365 days after initiation).
Statistical analyses
We calculated the proportions of real-world patients
meeting the eligibility criteria applied in the HPS (DM)
trial and of those meeting any single criterion for exclu-
sion (ﬁgure 1A). For both groups of patients deemed
either eligible or ineligible, we estimated the cumulative
hazard function for the composite end point using a
Nelson-Aalen estimator (ﬁgure 2A) in a stratiﬁed sur-
vival analysis from the date of the ﬁrst statin purchase
until the date of the composite end point or censoring.
As the CARDS trial included only patients without estab-
lished CVD at cohort entry, we determined the denom-
inator accordingly from the subgroup of real-world
patients presenting without CVD (ﬁgure 1B) and per-
formed similar analyses applying the eligibility criteria of
the CARDS trial (ﬁgure 2B). We regarded the risk of
CVD events during statin therapy as a function of the
patient’s background CVD risk and the effect of statins
in reducing CVD, as performed by Van Staa et al.30
Statin therapy reduced the relative risk of major CVD
events by 22% in the HPS (DM) trial11 and by 37% in
the CARDS trial.12 If it is assumed that statins had a
similar effect on our cohort members, the underlying
CVD risks would have been 22–37% higher than those
observed in this study.
We used descriptive statistics to determine the patient
characteristics and lipid-lowering interventions for all of
the cohort members and also separately for those
without CVD at statin initiation. We used the SAS release
9.2 program package (SAS Institute, Cary, North
Carolina, USA) for all of the statistical analyses.
RESULTS
Trial eligibility criteria and real-world patients
Altogether, 56 963 patients with diabetes initiated
statin use between 2005 and 2008 in Finland. Most of
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them, 73% (N=41 552), had no apparent CVD at
cohort entry. Fifty-seven per cent of the patients ful-
ﬁlled the eligibility criteria of the HPS (DM) trial
(ﬁgure 1A, see also online supplementary appendix
table), and 49% of those with no established CVD ful-
ﬁlled the criteria for the CARDS trial (ﬁgure 1B, see
also see online supplementary appendix table).
Patients with a recent CVD event were deemed ineli-
gible for both trials.
Among the initiators, a major CVD event occurred for
8714 patients (15%) during a mean follow-up of
3.4 years. There were 2499 acute myocardial infarctions,
3163 strokes, 1856 coronary procedures and 1196 CVD
deaths captured as ﬁrst events in the registers.
Altogether, 48 249 patients were censored: 2212 (4%)
died of non-CVD-related causes, 942 (2%) were institu-
tionalised and 45 095 (79%) reached the end of the
study period (31 December 2010) without a major CVD
event. For patients not meeting the eligibility criteria of
the HPS (DM) trial, the cumulative risk of a CVD event
occurring was two to three times higher compared to
those who were eligible, whereas the cumulative risk for
a CVD event occurring among the patients eligible or
ineligible for the CARDS trial, all without established
CVD, was of the same magnitude (ﬁgure 2).
Patient characteristics
Table 1 presents the descriptive characteristics for all of
the real-world patients, as well as separately for those
without CVD, for comparison with the data from the
HPS (DM) and CARDS trials.
The respective data on medication use can be found
in table 2.
Compared with the HPS (DM) population, the real-
world patients were less often male. The mean age was,
however, well balanced, the proportions of those
younger than 65 years being about 60%. The proportion
of patients with CVD (or CHD) was lower (27% vs
51%), and the mean duration of diabetes was shorter
(7.6 vs 9.3 years) among the real-world patients than in
the HPS (DM) trial. Compared with the CARDS partici-
pants, real-world patients without established CVD were
also less often male and were younger. Speciﬁcally,
within the age bracket 40–75 years, 53% of the real-
world patients (N=34 682) were younger than 60 years,
the corresponding proportion being 39% in the CARDS
trial. The mean duration of diabetes was well balanced
between the real-world patients and the CARDS partici-
pants. Newly diagnosed diabetes was an exclusion criter-
ion in the CARDS trial, whereas 14% of the real-world
patients belonged to that group. Use of antihypertensive
Table 1 Characteristics of the real-world patients with diabetes and initiating statin therapy and of the participants of the
HPS-DM11 and CARDS12 trials
Study population HPS-DM11
Real-world
patients with
diabetes (all)
CARDS12 (see online
supplementary
appendix)
Real-world patients
with diabetes and
without CVD*
Years of recruitment or cohort entry 1994–1997 2005–2008 1997–2001 2005–2008
Number of patients 5963 56 963 2838 41 552
Mean age in years (SD) 62.1 (8.9) 61.9 (12.4) 61.5 (8.3) 59.5 (12.0)
Min 40 8 40 8
Max 80 98 75 96
Age in years, N (%)
<40 2384 (4) 2266 (5)
40–80 50 347 (88) 37 622 (91)
≥80 4232 (7) 1664 (4)
Men, N (%) 4147 (70) 31 912 (56) 972 (68) 22 605 (54)
Cardiovascular disease, N (%) 3051 (51) 15 411 (27) 0† 0
Coronary heart disease, N (%) 1981 (33) 11 054 (19) 0† 0
Previous myocardial infarction, N (%) 1125 (19) 3742 (7) 0† 0
Stroke, N (%) NA 3713 (7) 0† 0
Peripheral arterial disease, N (%) NA 2046 (4) 0† 0
Type I diabetes, N (%) 615 (10) 4463 (8) 0 3644 (9)
Diabetes duration in years (SD) 9.3 (8.9)‡ 7.6 (8.5) 7.9 (6.4) 7.1 (8.2)
Diabetes duration ≤ 0.5 years, N (%) NA 7514 (13) 0† 5638 (14)
Retinopathy, N (%) NA 4569 (8) 426 (30) 3051 (7)
Microalbuminuria/macroalbuminuria, N
(%)
NA 124 (<1) 172 (12) 84 (<1)
Nephropathy, N (%) 0† 441 (<1) 0† 232 (<1)
For the CARDS trial, only data for the arm treated with statins (N=1428) are presented.
*According to previous cardiovascular disease (CVD) status at baseline.
†Assumed on the basis of trial eligibility criteria.
‡Data for patients with type 2 diabetes.
CARDS, Collaborative Atorvastatin Diabetes Study; HPS-DM, Heart Protection Study-diabetes mellitus; NA, data not available.
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Figure 1 (A) Flow chart of real-world patients fulfilling a criterion for exclusion in the Heart Protection Study11 or fulfilling all eligibility criteria. (B) Flow chart of real-world
patients fulfilling a criterion for exclusion in the Collaborative Atorvastatin Diabetes Study12 or fulfilling all eligibility criteria.
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medication and metformin was more common, and the
use of sulfonylureas less common, among the real-world
patients than among participants in both trials.
Lipid-lowering interventions
We give the distributions for statin doses at initiation
and during the second half of the ﬁrst year of follow-up
as simvastatin equivalents in table 3.
About one-quarter (27%) of all the real-world patients
and 29% of those without CVD had a statin prescribed
at a dose corresponding to <20 mg of simvastatin. These
proportions did not change appreciably during the
1-year follow-up. Only 1% used ﬁbrates at statin initi-
ation (N=607 for all of the patients and N=406 for those
without CVD).
For the real-world patients, the mean MPR was 72%
for a mean follow-up of 3.4 years. The proportion of sur-
vivors with good adherence to statins (MPR ≥80%)
decreased gradually from 63% (32 886/51 905) at the
end of the ﬁrst year of follow-up to 42% (4059/9626) at
Figure 2 (A) Cumulative hazard for major vascular events among real-world patients with diabetes deemed eligible and
ineligible for the Heart Protection Study.11 (B) Cumulative hazard for major vascular events among real-world patients with
diabetes with no cardiovascular disease and deemed eligible and ineligible for the Collaborative Atorvastatin Diabetes Study.12
Table 2 Medications used by the real-world patients with diabetes and initiating statin therapy and those used by
participants in the HPS-DM11 and CARDS12 trials
Study population HPS-DM11
Real-world patients
with diabetes (all)
CARDS12 (see online
supplementary appendix)
Real-world patients with
diabetes and without
CVD*
Number of patients 5963 56 963 2838 41 552
Diabetes treatment, N (%)
Diet only NA (21) 8325 (15) 214 (15) 5418 (13)
Insulin NA (25†) 15 564 (27) 282 (20) 10 874 (26)
Metformin NA (31) 34 606 (61) 672 (47) 26 716 (64)
Sulfonylurea NA (42) 16 312 (29) 730 (51) 11 059 (27)
Other oral agents NA 4363 (8) NA 3595 (9)
Treated hypertension or
drugs lowering blood
pressure, N (%)‡
2398 (40) 42 885 (75) 956 (67) 28 818 (69)
Blood pressure lowering drugs, N (%)
β-blockers NA 23 898 (42) 219 (15) 13 248 (32)
Calcium antagonists NA 13 686 (24) 304 (21) 8967 (22)
ACE inhibitors or
angiotensin II receptor
antagonists
NA 32 683 (57) 637 (45) 22 557 (54)
Diuretics NA 11 942 (21) 262 (18) 6616 (16)
For the CARDS trial, only data for the statin treated arm (N=1428) are presented.
*According to previous cardiovascular disease (CVD) status at baseline.
†Data for patients with type 2 diabetes.
‡Diuretics, β-blocking agents, calcium channel blockers and agents acting on the renin–angiotensin-pathway for the study cohort.
CARDS, Collaborative Atorvastatin Diabetes Study; HPS-DM, Heart Protection Study-diabetes mellitus; NA, data not available.
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the end of the ﬁfth year, the average proportion for all
ﬁve study years being 57%. The corresponding propor-
tions for the original HPS study participants were 89%
and 82%, respectively, with an average proportion of
85%. In the CARDS trial, the proportion of participants
with good adherence to lipid-lowering interventions was
90% for the ﬁrst year, 78% for the fourth year (last avail-
able) and 85% on average.
DISCUSSION
Limitations in representativeness for the real-world dia-
betes care were found when HPS (DM) and CARDS
trials were compared with population level data.
Approximately half of the real-world statin initiators with
diabetes would have qualiﬁed for these two landmark
randomised controlled trials. The background CVD risk,
approximated by the cumulative risk for major CVD
events after statin initiation, was either of the same mag-
nitude or remarkably higher among those deemed ineli-
gible in comparison with those eligible for the trials.
Women were under-represented in both trials, and con-
comitant antihypertensive medications and metformin
were more commonly used in the real-world setting.
Furthermore, almost 30% of the real-world patients were
prescribed statin doses that were lower than those used
in the trials, and about 40% of the patients did not
adhere to their statin therapy.
In RCTs, the legitimate aim of applying often strict eli-
gibility criteria is to obtain a homogeneous trial popula-
tion with minimum noise. This may, however, limit the
representativeness of the RCTs for real-world clinical
care.15 31–33 Yet, for the limitations in representativeness
to have clinical impact, they would have to question the
applicability of the trial ﬁndings for real-world clinical
care. That is, they would have to modify the relative or
absolute treatment effects of statins on CVD as they are
translated to real-world settings from the trials.15 The
proportions of patients deemed eligible in our study
were similar to those recently reported in the UK for
RCTs on novel oral anticoagulants (48–64%)34 and for
the UK Prospective Diabetes Study (32–51%)35 but
clearly higher than those for various other RCTs on
intensive glucose lowering (4–36%).35 The background
risk, reﬂected in the cumulative risk for CVD events
after statin initiation among patients deemed ineligible,
was either similar or remarkably higher as compared
with those eligible. Correspondingly, the CVD event rate
observed in the CARDS trial (about 10% in the placebo
arm in 4 years)12 approximates the event rates observed
in our study for those without CVD and deemed eligible
or ineligible for CARDS. Absolute risk reduction asso-
ciated with statin therapy in diabetes depends on the
background risk for CVD events.11 13 14 Therefore, it
seems reasonable to expect that the absolute risk reduc-
tion among all real-world patients with diabetes and
without CVD has been of the same magnitude as that
observed for patients with diabetes in CARDS. However,
the event rate of the real-world patients meeting the eli-
gibility criteria of the HPS (DM) trial was lower than
that observed in the trial (about 20% in the placebo
arm in 4 years).11 This may be explained by our ﬁnding
on the larger proportion of real-world patients present-
ing without CVD at statin initiation. Also, the event rate
was clearly higher for the patients deemed ineligible for
HPS (DM). This, for comparison, may reﬂect the trial
exclusion of high-risk patients with recent CVD events
who are yet likely to beneﬁt from intensive statin
therapy.36 Still, the average event rate for all of the initia-
tors, regardless of eligibility, was similar to the rate of
major CVD events in the HPS (DM) trial (data not
shown).
Both reviewed trials included fewer women and the
use of antihypertensive medications and metformin was
less common than in clinical practice. In addition, the
HPS (DM) trial was under-representative regarding
patients without CVD. Overall, the observations reﬂect a
changing scenario of treatment over the years. Most of
the placebo controlled statin RCTs, including CARDS
and HPS (DM), recruited their participants with
Table 3 Distributions (number and proportion) of statin doses as simvastatin equivalents at initiation and after 1 year of
follow-up according to statin prescriptions redeemed by all patients with diabetes and by those without cardiovascular disease
at statin initiation between 2005 and 2008 and surviving the following first year
Real-world patients with
diabetes (all)
Real-world patients with
diabetes and without
cardiovascular disease
Total number of patients N=45 463 N=33 219
Simvastatin (C10AA01) equivalent dose* At initiation After follow-up At initiation After follow-up
5 mg 142 (<1) 185 (<1) 105 (<1) 142 (<1)
10 mg 12 180 (27) 11 079 (24) 9645 (29) 8671 (26)
20 mg 23 671 (52) 23 065 (51) 17 803 (54) 17 364 (52)
40 mg 7178 (16) 8508 (19) 4097 (12) 5261 (16)
80 mg 2017 (4) 2197 (5) 1409 (4) 1518 (5)
>80 mg 225 (<1) 368 (<1) 120 (<1) 216 (<1)
*For equivalence, atorvastatin 10 mg=fluvastatin 80 mg=lovastatin 40 mg=pravastatin 40 mg=simvastatin 20 mg ≤rosuvastatin 5 mg.29
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diabetes by the year 2001 or earlier.11 12 37–40 Since then,
the diagnostic criteria for diabetes have broadened, and
the recommendations for screening, nutrition and self-
management have intensiﬁed.3–5 41 42 Statins are
initiated in the earlier stages of the disease8 9 and the
risk of CVD events associated with female gender is
acknowledged.16 19 43 The role of metformin in the
front line of therapy has become stronger,44–46 and the
use of sulfonylureas has declined.44–46 This trend has
been accompanied by improvements in blood pressure
control44 45 47 and a decline in mortality in diabetes.48
The relative treatment effects of statins in CVD preven-
tion in diabetes are constant regardless of gender, age,
prior CVD, diabetes duration and the use of antihyper-
tensive treatment.11 Therefore, the aforementioned
deviations in patient characteristics and concomitant
medications between the real-world clinical care and the
reviewed trials are not expected to modify the relative
treatment effects. However, the relative and absolute
effects of statins vary with the type and dose of the statin
intervention.11 12 Our ﬁndings support the common
notion that the cumulative statin doses and adherence
to statin therapy in the real world are lower than in the
RCTs.27 49 50 This may attenuate the beneﬁt and high-
lights the need for more appropriate implementation of
evidence-based statin therapies in the real world.
Strengths and limitations
This is the ﬁrst study to evaluate the representativeness
of statin trials for real-world statin initiators with diabetes
in terms of eligibility criteria, participant characteristics
and medication use. The validity of our data for captur-
ing real-world patients with pharmacologically treated
diabetes in clinical practice in Finland is good.51
However, our study has some limitations owing to our
reliance on register data. We have missed some patients
with diabetes, especially among persons aged 65 years or
more, who either had undiagnosed diabetes or who
were on diet therapy only and had not received any hos-
pital care.51 We had no data on liver function tests, chol-
esterol levels or smoking habits, and the actual date of
diabetes onset was estimated using the ﬁrst diabetes-
related record in any of the registers. In addition, some
complications, such as retinopathy, microalbuminuria
and nephropathy, are likely to have been under-
ascertained. Furthermore, the validity of our data on
capturing clinically determined diabetes subtype has not
been studied. Therefore, we were not able to deﬁne the
eligibility criteria exactly in the same way that the
reviewed trials had done, and we may have slightly
underestimated or overestimated the proportions of eli-
gible patients. While our dose assumption of one tablet
per day is likely to reﬂect the prescribed statin dose,52
actual statin use could not be veriﬁed from the prescrip-
tion register. Our study population included statin initia-
tors only, and long-term users and non-users were
excluded. Additionally, we focused on statin initiations
from 2005 to 2008, and therefore our study populations
may not reﬂect the current patients. In order to update
the results, we analysed the characteristics of all statin
initiators with diabetes in 2010 (N=12 541).We did not
observe any appreciable changes in the age proﬁle, pro-
portion of men, proportion of those with medically
treated hypertension or the proportion of patients with
CVD, nor in the mean duration of diabetes (data not
shown). However, the use of metformin was even more
common (68%), and the use of other orally adminis-
tered antidiabetic agents was of the same magnitude as
that of sulfonylureas (12% and 13%, respectively). In
addition, there was a shift towards higher statin doses:
only one-ﬁfth of the patients in 2010 initiated their
statin use with a dose corresponding to <20 mg of sim-
vastatin. Finally, diabetes care, including treatment of
dyslipidaemia, is constantly evolving53 and our assess-
ment represents a case study in Finland. Although the
prevalence of statin use in diabetes in Finland seems to
be at an average level,54 the treatment practices vary
between countries.55 Thus, similar evaluations of the
representativeness of RCTs with respect to the care of
patients with diabetes in other countries are needed.
Conclusions
Only half of the real-world patients initiating statin use
would have qualiﬁed for two landmark trials on statin
use in persons with diabetes, the HPS (DM) and
CARDS, limiting their representativeness for clinical
practice. Women and users of antihypertensive agents
and metformin were under-represented in both trials.
These deviations reﬂect the changes in diabetes treat-
ment over the years and are not expected to modify the
average treatment effects of statins on CVD. Prescribing
of lower statin doses in clinical practice than those used
in the reviewed trials and lower adherence may, however,
attenuate the beneﬁts in the real world when compared
with the RCTs.
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